Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JH013 in Healthy Subjects
NCT06633055Phase 1Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, triple-blind trial of JH013 in Sjogren's syndrome and systemic lupus erythematosus (SLE) (4 cohorts). Primary endpoint: Safety metrics at Day 57. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
JH013
03
Conditions
Sjogren's syndromesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06633055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633055.